Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Harmony Biosciences Holdings Inc HRMY

Healthcare Biotechnology
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.


NDAQ:HRMY - Post by User

Harmony Biosciences Holdings Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jun 02, 2022 7:51am
138 Views
Post# 34725736

PITOLISANT IS A “PORTFOLIO IN A PRODUCT” OPPORTUNITY!

PITOLISANT IS A “PORTFOLIO IN A PRODUCT” OPPORTUNITY!
Harmony Biosciences, Inc. (NASDAQ: HRMY) is a commercial-stage biopharmaceutical company developing novel therapeutics for rare and orphan diseases, focusing on central nervous system disorders. Pitolisant, its lead product candidate, is a first-in-class histamine 3 (H3) receptor antagonist/inverse agonist that can help treat excessive daytime sleepiness (EDS), narcolepsy, and cataplexy. 
 
We take a look at what's in the pipeline for Harmony Biosciences!

Read on to know more:

https://www.aviseanalytics.com/pitolisant-is-a-portfolio-in-a-product-opportunity/

 
 
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities